HC Wainwright & Co. Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has initiated coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and set a price target of $9.
December 08, 2023 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Solid Biosciences with a Buy rating and a price target of $9.
The initiation of coverage by HC Wainwright & Co. with a Buy rating typically indicates a positive outlook on the stock, suggesting that the analyst sees potential upside. The announcement of a price target of $9, which is presumably higher than the current trading price, is likely to be viewed positively by investors and could lead to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100